Healthcare Review: Sequenom, Anika Therapeutics, Cigna, Discovery Laboratories, CytRx Print E-mail
By Staff and Wire Reports   
Thursday, 31 October 2013 13:13
U.S. stocks fell modestly on Thursday, with investors cautious with indexes near record levels as they digested recent comments from the Federal Reserve, though some strong corporate earnings provided a reason to buy. Optimism about earnings was boosted by Exxon Mobil Corp., one of the largest U.S. companies by market cap, which reported adjusted third-quarter earnings that beat expectations, sending shares 1.1 percent higher to $89.78.

Sequenom ($SQNM) falls hard on news the U.S. District Court for the Northern District of California has invalidated a patent related to fetal cell-free DNA detection. Ultimately, the court ruled in favor of Ariosa Diagnostics in finding that the patent sought to cover a natural phenomenon.

Anika Therapeutics ($ANIK) rallies sharply after breezing past the Street's profit expectations for Q3.Revenue rises 20% Y/Y while net income jumps 212% helped by an easy compare with Q3 2012. Cingal clinicals contribute to a 33% Y/Y increase in R&D. Cash position at quarter's end was $64.1M versus $44.1M as of December 31, 2012. Gross product margin rises 19%, helped by "ongoing initiatives to realize planned operational efficiencies, as well as more favorable product mix and the elimination of the unprofitable tissue engineering operations."

Shares of Cigna ($CI) rally as Q3 results top estimates. Revenues rise 10% Y/Y in Q3, while adjusted income from operations jumps 12%.Premiums and fees growth by segment: Global Health Care, +7%; Global Supplemental Benefits, +29%; Group Disability and Life, +9%.FY13 outlook: $6.70-6.90/share versus previous guidance of $6.25-6.65/share and against consensus of $6.65.

Discovery Laboratories ($DSCO) shares are tumbling after the company priced a 25M share offering (3.75M share overallotment) at $2/share. Outstanding shares will be diluted by 46%.The company expects to take $47M to the bank after fees. The offering was bound to come after shares surged when the FDA approved the company's updated specifications for Surfaxin.

CytRx ($CYTR) is out with some interim data from a Phase 2b trial of aldoxorubicin versus doxorubicin as a first-line treatment for advanced soft tissue sarcomas. ORR for the aldoxorubicin group was 22% versus 0% for the doxorubicin group and CYTR says only 32% of patients that received aldoxorubicin experienced progressive disease versus 50% of patients who received doxorubicin. SAEs: 24 for aldoxorubicin versus 6 for doxorubicin (ultimately, none of the SAEs required discontinuation of treatment).Top-line PFS data is expected in December.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter